Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Cygnus' Glucowatch

This article was originally published in The Tan Sheet

Executive Summary

Cygnus' Glucowatch: Rights sold to Becton Dickinson for $20 mil. under an agreement announced Feb. 14. BD's $20 mil. commitment for the non-invasive blood glucose meter consists of an upfront equity investment and milestone payments based on further progress toward bringing the device to market. In return, BD is gaining exclusive rights to the development-stage GlucoWatch except for Japan and Korea. Cygnus retains manufacturing rights to the Glucowatch, responsibility for completing development of the device and securing FDA approval, and will provide customer support to BD in marketing the wrist watch-type device. Cygnus reportedly will receive royalties from BD of 50% or more on Glucowatch profits...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084791

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel